Table 2 Univariate analyses of clinical and biochemical markers in relation to response to sunitinib

Total

8(21)

30(79)

26(68)

12(32)

Age

0.69

0.73

  < 63.1

4(17)

19(83)

15(65)

8(35)

  ≥ 63.1

4(27)

11(73)

11(73)

4(27)

Sex

0.17

0.45

 Female

4(40)

6(60)

8(80)

2(20)

 Male

4(14)

24(86)

18(64)

10(36)

Number of disease sites

0.71

0.31

  ≤ 2

3(18)

14(82)

10(59)

7(41)

  > 2

5(24)

16(76)

16(76)

5(24)

Prior nephrectomy

0.26

0.73

 Yes

6(29)

15(71)

15(71)

6(29)

 No

2(12)

15(88)

11(65)

6(35)

Pretreatment hypertension⁶

0.70

0.30

 Yes

5(26)

14(74)

15(79)

4(21)

 No

3(16)

16(84)

11(58)

8(42)

Treatment induced eHTN⁷ ≤ week 6

1.00

0.70

 Yes

4(23)

13(77)

13(76)

4(24)

 No

4(27)

11(73)

10(67)

5(33)

Treatment induced eHTN⁸ ≤ week 12

0.53

0.04

 Yes

5(33)

10(67)

13(87)

2(13)

 No

0(0)

4(100)

1(25)

3(75)

IMDC risk

0.77

0.46

 Good

2(29)

5(71)

6(86)

1(14)

 Intermediate

3(25)

9(75)

9(75)

3(25)

 Poor

3(18)

14(82)

10(59)

7(41)

NLR baseline ≤3

1.00

0.46

 Yes

5(23)

17(77)

16(73)

6(27)

 No

3(25)

9(75)

7(58)

5(42)

NLR week 6 ≤ 3

0.32

0.15

  ≤ 3

7(23)

23(77)

22(73)

8(27)

  > 3

0(0)

6(100)

2(33)

4(67)

NLR shifted from >3 to ≤3 at week 6

1.00

0.06

 Yes

2(25)

6(75)

6(75)

2(25)

 No

0(0)

3(100)

0(100)

3(100)

NLR shifted from ≤3 to >3 at week 6

1.00

0.50

 Yes

0(0)

2(100)

1(50)

1(50)

 No

5(26)

14(74)

14(74)

5(26)

CRP ≤10 (mg/L)

0.01

0.09

 Yes

7(41)

10(59)

14(82)

3(18)

 No

1(5)

19(95)

11(55)

9(45)

EORTC QoL symptom scale at BL⁹

0.31

0.02

 Upper quartile

0(0)

7(100)

2(29)

5(71)

 Lower 3 quartiles

8(27)

22(73)

24(80)

6(20)